Home › Peptides › Thymosin Alpha-1
Thymosin Alpha-1 dosage and protocol
Thymosin Alpha-1 is a thymic peptide that modulates and enhances immune function. It has been used clinically for hepatitis B, hepatitis C, and in cancer immunotherapy. Promotes T-cell differentiation, enhances NK cell activity, and has antiviral and anti-tumor properties. Marketed as Zadaxin in some countries.
- Vial size: 5 mg
- Reconstitution: 3 mL bacteriostatic water
- Concentration: 1.67 mg/mL
- Administration: subcutaneous
Research areas
- Immune Enhancement
- Antiviral
- Cancer Research
- T-Cell Activation
- Autoimmune Modulation
Quick start
- Reconstitute: Add 3.0 mL bacteriostatic water → ~1.67 mg/mL concentration
- Typical daily range: 300–500 mcg once daily (gradual titration)
- Easy measuring: At 1.67 mg/mL, 1 unit = 0.01 mL ≈ 16.7 mcg on a U-100 syringe
- Storage: Lyophilized at 2–8°C or −20°C; after reconstitution, refrigerate at 2–8°C and use within 7 days
Dosing protocol
| Phase | Dose | Frequency | Volume |
|---|---|---|---|
| Week 1 | 300 mcg | Once daily (SC) | 0.18 mL (18 units) |
| Weeks 2–8 | 500 mcg | Once daily (SC) | 0.30 mL (30 units) |
How it works
Thymosin alpha-1 (thymalfasin) is a 28-amino-acid peptide originally isolated from thymus tissue. It acts on innate immune cells partly through Toll-like receptors such as TLR2 and TLR9 on dendritic cells, activating signalling that promotes antigen presentation and the release of cytokines favouring a Th1 (cell-mediated) response. It also supports maturation of T cells and has been reported to enhance natural killer cell activity. These effects are why it has been studied as an immune enhancer in chronic viral infections, as a vaccine adjuvant in people with weak responses, and alongside cancer therapy. Thymalfasin is marketed as Zadaxin in a number of countries, mainly for chronic hepatitis B and as an immune adjunct; it is not FDA-approved in the United States. Clinical trials in hepatitis B and C have shown mixed results, with some studies reporting improved viral response when combined with interferon. Studies in sepsis and in cancer patients receiving chemotherapy have reported immune and outcome benefits, but many were small or open-label. It has a long record of good tolerability. Labelled regimens in approved markets commonly use 1.6 mg twice weekly, which differs from the daily microgram schedule in this record.
Reconstitution steps
- Draw 3.0mL bacteriostatic water with a sterile syringe
- Inject slowly down the vial wall; avoid foaming
- Gently swirl/roll until dissolved (do not shake)
- Label with reconstitution date and refrigerate at 2–8°C, protected from light
Storage
Store lyophilized at 2–8°C or freeze at −20°C for long-term. After reconstitution, refrigerate at 2–8°C and use within 7 days. Avoid freeze–thaw cycles.
Important notes
- Research use only
- FDA-approved equivalent (Zadaxin) used in 37 countries
- Well-tolerated with minimal side effects
- Powerful immunomodulator for viral and cancer research
- Often stacked with BPC-157 or TB-500 in recovery protocols
Supplies
- Bacteriostatic water
- Insulin syringes
- Alcohol swabs